{"analyses":[{"ciLowerLimit":"0.32","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","groupDescription":"AFP \\<400 ng/mL and stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0019","paramType":"Hazard Ratio (HR)","paramValue":"0.50","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","groupDescription":"AFP \\>/= 400 ng/mL and stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0879","paramType":"Hazard Ratio (HR)","paramValue":"0.67","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"11.73","upperLimit":"NA","value":"13.93"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"title":"AFP <400 ng/mL"},{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"5.75","upperLimit":"NA","value":"9.10"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"10.15","upperLimit":"NA","value":"12.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"AFP >/=400 ng/mL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause. Subpopulations with baseline AFP \\<400 ng/mL and AFP\\>/= 400 ng/mL were analyzed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEAN","populationDescription":"Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"Overall Survival by Baseline AFP in the Global Population","type":"SECONDARY","unitOfMeasure":"months"}